Craig Venter, "Hopeless Businessman" | GenomeWeb

Craig Venter says that he has been "successful in is finding alternate ways to fund research," in the New York Times. A venture capitalist friend, Alan Walton, adds that "Craig is just a hopeless businessman." Venter began Synthetic Genomics as a way to fund his research in synthetic biology, and his work there has garnered attention — Venter notes he heard from the president and the pope on the same day after announcing the activation of a synthetic genome.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.